Drug safety evaluation of naltrexone/bupropion for the treatment of obesity
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Obesity is a known health risk for the development of several preventable diseases. Obesity-related metabolic alterations negatively impact different physiological mechanisms, which supports the rationale for the use of combined drug therapy. Naltrexone is an opioid antagonist for the treatment of opioid and alcohol dependency, whereas bupropion is a norepinephrine/dopamine reuptake inhibitor used to treat depression and smoking cessation. Although not effective as individual monotherapies for obesity, naltrexone and bupropion in combination produce weight loss and a metabolic profile beneficial for the potential treatment of obesity. AREAS COVERED: This review examines the safety and antiobesity effects of naltrexone and bupropion alone and in combination. It reviews the results of four Phase III clinical trials of a novel fixed dose of sustained-released naltrexone/bupropion. EXPERT OPINION: Naltrexone/bupropion has a greater weight loss efficacy than two FDA-approved medications, orlistat and lorcaserin. Although the weight loss produced by phentermine/topiramate is superior to naltrexone/bupropion, the safety profile of naltrexone/bupropion has less severe adverse effects. In addition, naltrexone/bupropion is well tolerated, with nausea being the most reported adverse event. Unlike other centrally acting medications, lorcaserin and phentermine/topiramate, naltrexone/bupropion has no abuse potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Picot, J., Jones, J., Colquitt, J., Gospodarevskaya, E., Loveman, E., Baxter, L., & Clegg, A. (2009) · Health Technology Assessment · doi:10.3310/hta13410 · Cited by 1,066 · cited 1×
“In more at-risk obese individuals with a BMI of ‡ 40 kg/m(2) (class III) or a BMI ‡ 35 kg/m(2) with one or more obesity-related comorbidities, bariatric surgical options are considered as well [9-11].”
BackgroundEffect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
James, W. P. T., Caterson, I. D., Coutinho, W., Finer, N., Van Gaal, L. F., Maggioni, A. P., Torp-Pedersen, C., Sharma, A. M., Shepherd, G. M., Rode, R. A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003114 · Cited by 943 · cited 1×
“Although a long-term outcome trial for cardiovascular end points, similar to SCOUT for sibutramine [26], has not been performed with phentermine/topiramate, these findings demonstrating blood pressure reductions suggest that the weight loss caused by phentermine/topiramate could offset the more significant adverse obe…”
ResultLong term pharmacotherapy for obesity and overweight: updated meta-analysis
Rucker, D., Padwal, R., Li, S. K., Curioni, C., & Lau, D. C. W. (2007) · BMJ · doi:10.1136/bmj.39385.413113.25 · Cited by 801
Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0234 · Cited by 501
Bupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research · doi:10.1038/oby.2002.86 · Cited by 315
Fryer, J. D., & Lukas, R. J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37928-5 · Cited by 283
Bupropion SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms
Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., Leadbetter, R. A., Richard, N., Haight, B., Jamerson, B. D., et al. (2002) · Obesity Research · doi:10.1038/oby.2002.142 · Cited by 205
Bipolar depression: issues in diagnosis and treatment
Thase, M. E. (2005) · Harvard Review of Psychiatry · doi:10.1080/10673220500326425 · Cited by 89 · cited 1×
“Based on its low affinity for the 5HT transporter, it is not associated with sexual dysfunction or weight gain, which is typically observed with some selective serotonin reuptake inhibitors (SSRIs), thus bupropion is considered an atypical antidepressant [57-59].”
Background
Cited by
Cardiovascular risk and obesity
Cercato, C., & Fonseca, F. A. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0468-0 · Cited by 395
Investigational glucagon-like peptide-1 agonists for the treatment of obesity
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1221925 · Cited by 25
Mooney, L. J., Hillhouse, M. P., Thomas, C., Ang, A., Sharma, G., Terry, G., Chang, L., Walker, R., Trivedi, M., Croteau, D., et al. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000218 · Cited by 25
“…most commonly reported medication-related AE and comprised one-third of all study medication-related AEs; this is consistent with studies of naltrexoneþBRP as a combination treatment for obesity in which nausea has been reported as the most commonly associated side effect (Verpeut and Bello, 2014).”
Result
Metadata
- Authors
- Verpeut, J. L., & Bello, N. T.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2014-04-28
- Volume
- 13
- Issue
- 6
- Pages
- 831-841
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2020370186
- Cited by
- 202
- References
- 12
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. https://app.cochat.ai/papers/10.1517/14740338.2014.909405
- The paper
- Verpeut, J. L., & Bello, N. T. (2014). Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740338.2014.909405
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.